Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of screening
• People who have tumor tissue available for testing, either as a preserved tissue block or slides from a biopsy
• People who have had a test to check their PD-L1 status (a marker found on some cancer cells) through local testing
• People whose major organs (such as liver, kidneys, and bone marrow) are functioning well enough to meet the trial's requirements
• People with a general health and activity level rated as 0 or 1 on a standard medical scale, meaning they are either fully active or have minor restrictions in physically strenuous activity but can carry out light work
• Part A only: People who have been newly diagnosed with early-stage or locally advanced (Stage II or IIIA/B) non-small cell lung cancer (NSCLC) that has not yet been treated, has been confirmed by a pathology test, and has been assessed by a specialist team — including a lung cancer surgeon — as suitable for surgery, with a plan to receive treatment before surgery
• Part B only: People who have been confirmed by pathology to have early-stage or locally advanced (Stage II or IIIA/B) NSCLC, have already had complete surgical removal of the tumour, are considered suitable for treatment after surgery, and did not have a complete disappearance of cancer cells from surgery after standard pre-surgery chemotherapy and immunotherapy
• Part C only: People who have been confirmed by pathology to have locally advanced, inoperable (Stage III) NSCLC, and have already completed a course of radiation therapy of at least 60 Gy and at least 2 cycles of standard platinum-based chemotherapy given alongside radiation, with results showing the cancer is stable or better

Who may not be able to join:

• People whose lung cancer has certain specific genetic changes known as EGFR or ALK mutations (confirmed testing showing these are absent is required for non-squamous type NSCLC)
• People who have cancer that has spread to the brain or spinal cord, or to the membranes surrounding the brain or spinal cord
• People who have a clinically significant risk of serious bleeding or abnormal connections forming between body passages (fistula)
• People who have been diagnosed with another cancer in the 3 years before starting the trial, or who still show signs of a previously diagnosed cancer
• People who still have side effects from previous cancer treatment that have not recovered to a mild or absent level
• People with a known history of a severe allergic reaction to any ingredient in the study treatment, or to similar types of antibody-based medicines
• People who have had an organ transplant or bone marrow/stem cell transplant from another person
• People with certain lung conditions, including non-infectious or medication-related inflammation of the lung tissue (ILD or pneumonitis), or severe lung disease unrelated to their cancer
• People who have had serious, uncontrolled health conditions in the 6 months before starting the trial, including uncontrolled heart or blood vessel conditions, high blood pressure, diabetes, major vascular disease, or serious blood clot events
• People who have had major surgery within 4 weeks, or minor surgery within 3 days, before starting the trial
• People with a history of serious bleeding problems or difficulty with blood clotting
• People who have had certain digestive or abdominal conditions within the 6 months before starting the trial, including oesophageal varices, severe ulcers, unhealed wounds, a hole in the gut wall, abdominal fistula, bowel obstruction, abdominal abscess, or acute gastrointestinal bleeding
• People with active or ongoing infections, or those who test positive for active HIV, Hepatitis B, or Hepatitis C
• People with a history of a weakened immune system (immunodeficiency)
• People with certain medical or psychiatric conditions that may make participation unsafe, including recent (within the past year) or active thoughts of self-harm or suicide (within the past 5 years), or abnormal laboratory results that may increase risk
• People who are breastfeeding, people who could become pregnant and are unwilling to use contraception, and male participants who are unwilling to follow the trial's contraceptive requirements

Important: Always verify eligibility with the trial site directly before applying.